EcoDrugPlus

Amyloid Beta (A4) Precursor Protein B

Ensembl ID : ENSOTSG00005013266
Gene Symbol: APPB
1 Cross references
199 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOTSG00005013696
Gene Symbol: APP
3 Cross references
196 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOTSG00005045345
Gene Symbol: APP
3 Cross references
196 Possible Orthologues:

Amyloid Beta Precursor Protein

Ensembl ID : ENSOTSG00005034599
Gene Symbol: APP
3 Cross references
196 Possible Orthologues:

Amyloid-Beta A4 Protein-Like

Ensembl ID : ENSOTSG00005000665
Gene Symbol: LOC112241784
3 Cross references
199 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOTSG00005039495
Gene Symbol: AR
1 Cross references
206 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOTSG00005012665
Gene Symbol: AR
3 Cross references
206 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSOTSG00005022912
Gene Symbol: AR
1 Cross references
206 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSOTSG00005006526
Gene Symbol: AGTR1
3 Cross references
193 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSOTSG00005002976
Gene Symbol: AGTR1
1 Cross references
193 Possible Orthologues:

Angiotensin Ii Receptor, Type 2

Ensembl ID : ENSOTSG00005009260
Gene Symbol: AGTR2
1 Cross references
179 Possible Orthologues:

Antithrombin-Iii-Like

Ensembl ID : ENSOTSG00005023767
Gene Symbol: LOC112250696
3 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).